Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Galapagos ( (NL:GLPG) ).
Galapagos NV announced the presentation of new in vitro data for its selective TYK2 inhibitor, GLPG3667, at the ACR Convergence 2025. The data indicates that GLPG3667 shows differentiation from other TYK2 inhibitors, with a unique pharmacological profile that may enhance its efficacy in treating SLE and DM. This development could strengthen Galapagos’s position in the competitive market for autoimmune disease treatments, potentially offering new therapeutic options for patients.
The most recent analyst rating on (NL:GLPG) stock is a Hold with a EUR27.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the NL:GLPG Stock Forecast page.
More about Galapagos
Galapagos NV is a biotechnology company focused on the discovery and development of small molecule medicines with novel modes of action. The company is engaged in the development of treatments for diseases such as systemic lupus erythematosus (SLE) and dermatomyositis (DM), with a particular emphasis on tyrosine kinase 2 (TYK2) inhibitors.
Average Trading Volume: 133,241
Technical Sentiment Signal: Hold
Current Market Cap: €1.84B
See more data about GLPG stock on TipRanks’ Stock Analysis page.